Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) patients with diabetes constitute a subgroup of patients with a high rate of liver-related complications.Currently, there are no specific drug recommendations for these patients.Metformin, a conventional insulin sensitizer agent, has been widely prescribed in patients with diabetes.Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible.To date, most studies have enrolled diabetic patients who are treated with metformin, with the drug being taken continuously throughout the study.Although evidence exists regarding the benefits of metformin for NAFLD in preclinical studies, reports on the efficacy of metformin in adult NAFLD patients have had some discrepancies regarding changes in liver biochemistry and hepatic fat content.Evidence has also suggested possible effects of metformin as regards the prevention of hepatocellular carcinoma tumorigenesis.This review was performed to comprehensively summarize the available in vitro, in vivo and clinical studies regarding the effects of metformin on liver steatosis for the treatment of adult NAFLD patients with diabetes.Consistent reports as well as controversial findings are included in this review, and the mechanistic insights are also provided.In addition, this review focuses on the efficacy of metformin as a monotherapy and as a combined therapy with other antidiabetic medications.(Gut Liver 2021;15:827-840)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · cited 1×
“Several epidemiological studies suggested that metformin had potential antitumor effect with potential effects in cancer prevention.(60,61) A large matched-paired cohort conducted in Taiwan found that metformin was associated with HCC incidence reduction in patients with T2DM with a hazard ratio of 0.”
BackgroundThe role of STAT3 in autophagy
You, L., Wang, Z., Li, H., Shou, J., Jing, Z., Xie, J., Sui, X., Pan, H., & Han, W. (2015) · Autophagy · doi:10.1080/15548627.2015.1017192 · Cited by 515 · cited 1×
“Additionally, metformin was shown to inhibit the STAT3 pathway,(20) the pathway in which inhibition also induced autophagy.(42) All these reports are summarized in Table 3.”
BackgroundInvolvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · cited 1×
“Metformin is taken up in the liver via organic cation transporter-1 (OCT1).(54) Hepatic uptake of various drugs via this transporter has been shown to have differ between species, for example between mice and humans.”
BackgroundMetformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Polyzos, S. A., Aronis, K. N., Kountouras, J., Raptis, D. D., Vasiloglou, M. F., & Mantzoros, C. S. (2016) · Diabetologia · doi:10.1007/s00125-015-3769-3 · Cited by 248
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235 · cited 1×
“5009/gnl20367 829 Leptin is an adipose tissue-produced peptide which decreases hepatic de novo fatty acid synthesis and promotes peroxisome proliferator-activated receptor gamma coactivator-1α (PPARα)-dependent fatty acid beta oxidation.(34) Circulating leptin levels were found to be higher in NAFLD patients than cont…”
BackgroundCuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122
Tian, F., Zheng, Z., Zhang, D., He, S., & Shen, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181304 · Cited by 80
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59 · cited 5×
“However, this effect was not observed in the liver in mice that had already developed NAFLD.(63) Another study of a HFD-fed, HCC model of transgenic zebrafish demonstrated the HFD enhanced malignancyrelated histologic and morphologic features.”
BackgroundInfluential
Cited by
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84
“Although metformin has shown anti-inflammatory properties and potentially positive effects on hepatic steatosis and steatohepatitis, by suppressing de novo lipogenesis, enhancing fatty acid oxidation, and promoting degradation of intracellular lipids that accumulate in hepatocytes [22,42] no significant improvement in…”
BackgroundDiabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Kim, I., Kyun, M.-L., Jung, H., Kwon, J.-I., Kim, J., Kim, J.-K., Lee, Y. B., Kwon, Y.-I., & Moon, K.-S. (2024) · ACS Omega · doi:10.1021/acsomega.4c02433 · Cited by 10
Metadata
- Authors
- Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N.
- Venue
- Gut and Liver
- Published
- 2021-11-15
- Volume
- 15
- Issue
- 6
- Pages
- 827-840
- ISSN
- 1976-2283 (ISSN-L)
- 2005-1212
- OpenAlex
- W3141405242
- Cited by
- 81
- References
- 15
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.